Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of June 2026, specifically reporting on share repurchase transactions executed between May 26, 2026, and May 29, 2026. The company is a global biopharma firm headquartered in London, United Kingdom.
Key Financial Metrics and Transaction Details
The filing details a share buyback program executed through Citigroup Global Markets Limited. The following table summarizes the daily purchase activity:
| Date | Shares Purchased | Lowest Price (GBp) | Highest Price (GBp) | VWAP (GBp) |
|---|---|---|---|---|
| 26 May 2026 | 301,200 | 1,900.00 | 1,942.50 | 1,922.09 |
| 27 May 2026 | 319,674 | 1,909.50 | 1,942.00 | 1,932.82 |
| 28 May 2026 | 307,448 | 1,906.00 | 1,935.50 | 1,921.76 |
| 29 May 2026 | 319,949 | 1,885.50 | 1,918.50 | 1,899.95 |
Cumulative Activity: Since May 11, 2026, the company has purchased 4,590,420 ordinary shares. The purchased shares are held as Treasury shares.
Capital Structure Post-Transaction:
- Treasury Shares: 265,968,706
- Shares in Issue (excluding Treasury): 4,050,256,108
- Total Voting Rights: 4,050,256,108
- Treasury Voting Rights Percentage: 6.57%
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares due to the buyback program. The filing does not report material changes to financial performance metrics compared to prior periods.
Guidance, Outlook, and Risks
Management Commentary: The share purchases were effected pursuant to a non-discretionary agreement entered into on May 8, 2026, and announced on May 11, 2026. The company confirms compliance with DTR 5.5.1R regarding the disclosure of treasury share percentages.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the 2025 Annual Report on Form 20-F and Q1 2026 Results. No specific new risks or contingencies are detailed in this document.
Investor Verification Checklist
- Verify the total number of shares in issue (4,050,256,108) for calculating ownership thresholds under FCA Disclosure Guidance and Transparency Rules.
- Confirm the 6.57% voting rights held in treasury to assess potential dilution or buyback impact on earnings per share.
- Review the full breakdown of individual purchases via the provided London Stock Exchange link for granular trading data.
- Consult the 2025 Form 20-F and Q1 2026 Results for comprehensive financial performance and risk factors not included in this transaction report.